Transdermal drug delivery system, over the past decades, has emerged as a major tool for treating diseases of the skin. The major underlying factor driving this method is that the human skin is the most readily accessible surface for the delivery of drugs. A transdermal patch is defined as a medicated adhesive patch which is placed on the skin for delivering a specific dose of medication through the layers of the skin and into the bloodstream. This patch is considered to be a self contained, discrete dosage form, when applied to the intact skin, would deliver the drug, through the skin at a controlled rate to the systemic circulation.
Transdermal drug delivery method is a non-invasive method which transports the drug from the surface of the skin to the circulatory system. The most effective medium for absorbing the drug is known to be the human skin. Patches are made on the skin through which this entire process is carried out. There are different types of patches which are used to introduce the active ingredients through the skin into the circulatory system. The transdermal delivery system broadly includes all topically administered drug formulations.
Transdermal drug delivery system has been proved to be efficient owing to its large advantages over other controlled drug delivery systems. Some of these advantages include the reduction of painful delivery and the first pass metabolism of the drugs. This system of drug delivery is considered to be user-friendly, convenient, and it offers the advantage of multi-day dosing. These factors have led to a significant increase in the rate of patient compliance.
There has been a significant upward trend in the global market for transdermal drug delivery. The market for transdermal drug delivery was worth US$ 25 billion in 2013 and is further anticipated to surpass US$ 40 billion by 2018. The major factor driving such a significant growth in the market is the increasing number of transdermal drug delivery products introduced into the market and continuously delivering therapeutic benefits in the real sense to the patients across the globe.
Inspite of the transdermal system being highly successful in niche market, in other therapeutic application areas, the growth of this segment has not been highly commendable. There is a huge potential which is attracting the various companies in the pharmaceutical and biotechnology space. There are many application areas which are currently being researched upon. Some of them are wound care, monitoring and diagnostic methods. In these areas, the skin is used as a major portal for the delivery of drugs into the human body. Thus, the application of this system of drug delivery is most likely to play a significant role in improving the quality of life.
Transdermal Drug Delivery Market Overview Favorable Market Drivers & Key Issues to be Discussed FDA & EMA Guidelines Transdermal Drug Clinical Pipeline by Phase, Disease & Country Transdermal Drug Profiles in Report: 250 Transdermal Drug in Clinical Phase: 87 Number of Marketed Transdermal Drugs: 55 Majority of Transdermal Drugs in Preclinical Phase: 26 Number of Discontinued & Suspended Drug Profiles: 108
Our reports have been used by over 10K customers, including:
Report Scope This report analyzes the market trends of microneedles with data from 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through the forecast period of 2021 to 2026). Regulatory scenarios, drivers, restraints and opportunities will be covered, as well as market shares for leading...
This report aims to provide a comprehensive study of the global market for transdermal drug delivery technologies/systems. It provides a detailed description of the different types of transdermal drug delivery systems (passive and active) and the current and historical market revenues.
175 pages •
By The Business Research Company
• Sep 2021
Major players in the autoinjectors market are AbbVie, Mylan, Eli Lilly and Company, Amgen, Becton Dickinson and Company, Johnson & Johnson, Teva Pharmaceutical, Merck, Pfizer, Bayer, Biogen, and AstraZeneca. The global autoinjectors market is expected to grow from $2.42 billion in 2020 to $2.94 billion in 2021 at a compound annual growth...
United States Connected Drug Delivery Devices Market, By Product Type (Connected Sensors v/s Integrated Connected Devices), By Technology (Bluetooth, Near Field Communication, Others), By Application (Asthma & COPD, Diabetes, Others), By End User (Healthcare Providers v/s Homecare), By Region, Competition Forecast & Opportunities,...
The global isosorbide market exhibited moderate growth during 2015-2020. Also known as D-Isosorbide dinitrate, isosorbide (C6H10O4) is a bio-product obtained from starch. The derivatives of isosorbide, namely isosorbide dinitrate and isosorbide mononitrate, find extensive applications across various end use industries...
693 pages •
By IQ4I Research & Consultancy Pvt. Ltd
• Jul 2021
Drug Delivery Systems (DDS) are the advanced formulations or technologies that modulate the release profile of therapeutic or prophylactic agents, their absorption, distribution and elimination characteristics to achieve the desired therapeutic effect and enhance the safety profile, patient convenience and compliance to medications...
Forecasts by Technology (Oral Drug Delivery Therapy, Injectable Drug Delivery, Topical Drug Delivery, Pulmonary Drug Delivery, Implantable Drug Delivery, Ocular Drug Delivery, Others), by Indication (Infectious Diseases, Cancer, Cardiovascular Diseases, Diabetes, Respiratory Diseases, Central Nervous System Disorders, Others), by Distribution...
Drug Delivery Technologies: Market Size From $1,451.50 billion in 2020, the global Drug Delivery Technologies market is projected to reach $3,203.09 billion by 2028. Based on our analysis the market is expected to grow at a CAGR of 10.4% from 2020 - 2028 timeframe. Some of the prominent trends that the market...
Microspheres: Market Size From $5.62 billion in 2020, the global Microspheres market is projected to reach $12.96 billion by 2028. Based on our analysis the market is expected to grow at a CAGR of 11.0% from 2020 - 2028 timeframe. Some of the prominent trends that the market is witnessing include, emerging economies...
175 pages •
By The Business Research Company
• May 2021
Major players in the liposomal drug delivery devices market are, Fudan-Zhangjiang, Pacira, Johnson and Johnson, Gilead Sciences, Novartis, Luye Pharma, CSPC, Ipsen (Onivyde), and Teva Pharmaceutical. The global liposomal drug delivery devices market is expected to grow from $3.304 billion in 2020 to $3.644 billion in 2021 at a compound...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.